GENT: Record 2025 sales, strong US growth, new partnership, and NT-proBNP development setback

About this update from Gentian Diagnostics Asa

Record sales and profitability were achieved in 2025, led by Cystatin C’s 32% growth and strong US expansion. A new exclusive partnership and high-sensitivity technology project were announced, while NT-proBNP assay development faced a setback. Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Gentian Diagnostics Asa